On April 8, 2024 (Effective Date), Prelude Therapeutics Incorporated and Laurent Chardonnet, the Company?s Chief Financial Officer, agreed that he will no longer serve as the Company?s Chief Financial Officer, effective as of the Effective Date. Effective as of the Effective Date, the Board of Directors of the Company appointed Bryant D. Lim, the Company?s Chief Legal Officer and Corporate Secretary, as its interim Chief Financial Officer. Accordingly, Mr. Lim will serve as the Company?s principal financial officer and principal accounting officer for the Company, pending an ongoing search for a permanent Chief Financial Officer.

Mr. Lim, age 53, has served as the Company?s Chief Legal Officer and Corporate Secretary since February 2023 and will continue in those roles in addition to his new role. Prior to joining the Company, Mr. Lim served as Senior Vice President, General Counsel and Chief Business Officer at Aceragen Inc. from September 2018 to February 2023, where he instituted and oversaw all legal, corporate governance and business development activities. Prior to that role, Mr. Lim served as the Vice President of Legal and Global Chief Compliance Officer at Incyte Corporation from May 2014 to September 2018.

Prior to Incyte, Mr. Lim held roles of increasing responsibility at ViroPharma Incorporated, Merck & Co. Inc. and Morgan, Lewis & Bockius LLP. Mr. Lim began his legal career as a law clerk for a federal judge.

Mr. Lim currently serves on the board of directors for Life Sciences of Pennsylvania, a role he has held since May 2019. Mr. Lim received a J.D. from Villanova University School of Law and a B.A. from the University of Rochester.